Liraglutide
Pharmaceutical Premium
Pharmaceutical API

Liraglutide

High-purity pharmaceutical grade Liraglutide manufactured to meet stringent USP/EP specifications for pharmaceutical formulations and research applications. Our pharmaceutical grade material delivers exceptional purity and consistency for critical pharmaceutical manufacturing.

  • USP/EP Grade Specifications
  • High Purity (≥99.0%)
  • Comprehensive Analytical Testing
  • Regulatory Compliance Documentation
  • Pharmaceutical Manufacturing Grade
  • Quality Assurance Certified
Request Quote Technical Support

Technical Specifications

Chemical Formula: C172H265N43O51
CAS Number: 204656-20-2
EINECS Number: Not Available
Molecular Weight: 3751.2 g/mol
Physical State: White to off-white lyophilized powder
Purity (HPLC): ≥95.0% (USP/EP Grade)
pH (1 mg/mL in water): 7.0-8.5
Water Content: ≤10.0% (Karl Fischer)
Residue on Ignition: ≤2.0%
Heavy Metals (as Pb): ≤20 ppm
Related Substances: ≤5.0% (total impurities)
Bioactivity: ≥90% (GLP-1 receptor activity)
Storage Conditions: Store at -20°C, protect from light
Shelf Life: 2 years from date of manufacture
Packaging Options: 5mg, 10mg, 25mg pharmaceutical vials

Applications

Injectable Formulations
Diabetes Medications
GLP-1 Receptor Agonist Therapy
Type 2 Diabetes Treatment
Diabetes Research
Hospital Endocrinology Units
Pharmaceutical Manufacturing
Antidiabetic Medications
Metabolic Research
Clinical Trials
Regulatory Submissions
Reference Standards

Industry-Specific Grades

DRAVYOM offers specialized Liraglutide grades tailored for specific peptide pharmaceutical requirements, ensuring optimal performance and regulatory compliance across diverse antidiabetic drug manufacturing applications.

USP Grade (United States Pharmacopeia)
Purity: ≥95.0% (HPLC) Related Substances: ≤5.0% Heavy Metals: ≤20 ppm Application: FDA-compliant formulations
EP Grade (European Pharmacopoeia)
Purity: ≥95.0% (HPLC) Impurities: Individual ≤2.0% Water Content: ≤10.0% Application: EU regulatory submissions
Peptide Research Grade
Purity: ≥98.0% (HPLC) Water Content: ≤5.0% Bioactivity: ≥95% Application: GLP-1 research
Reference Standard Grade
Purity: ≥99.0% (HPLC) Certified Analysis: COA included Traceability: NIST traceable Application: Analytical standards

Quality Standards

DRAVYOM's Liraglutide API is manufactured under stringent quality control protocols, meeting international pharmaceutical standards including USP, EP, and cGMP specifications. Our pharmaceutical-grade production ensures consistent performance and regulatory compliance.

cGMP Certified Manufacturing
USP/EP Grade Specifications
≥95.0% HPLC Purity
Advanced Analytical Testing
Bioactivity Verification
Cold Chain Logistics
Comprehensive Certificate of Analysis
Temperature-Controlled Storage

Advanced Chemical Properties & Performance

Liraglutide exhibits exceptional pharmaceutical properties essential for diabetes and obesity treatment applications. Its ultra-pure composition and precise molecular structure ensure reliable performance in demanding pharmaceutical formulations and therapeutic treatments.

Pharmaceutical Properties
Molecular Weight: 3751.2 g/mol
Solubility (Water): Highly soluble
Isoelectric Point: pH 8.15
Bioavailability: 55% subcutaneous
Physical Properties
Appearance: White to off-white powder
Crystalline Form: Lyophilized powder
Protein Content: ≥95% by HPLC
Reconstitution: Clear solution
Formulation Performance
Injection Preparation: Ready for formulation
Stability in Solution: 24 hours at 2-8°C
pH Stability: 7.0-8.5 optimal
Buffer Compatibility: Phosphate buffer preferred
Purity Specifications
Total Impurities: ≤5.0%
Related Peptides: ≤2.0% individual
Heavy Metals: ≤10 ppm
Residual Solvents: ICH Q3C compliant
Stability Properties
Shelf Life: 3 years (-20°C storage)
Light Sensitivity: Protect from light
Temperature Stability: Stable at -20°C
Freeze-Thaw Stability: Up to 3 cycles

Performance Characteristics

Detailed performance metrics demonstrate Liraglutide superiority in pharmaceutical applications with exceptional efficacy, bioavailability, and reproducibility across diverse formulation types and therapeutic protocols.

Therapeutic Performance

Bioavailability: 55% subcutaneous injection

Excellent therapeutic effectiveness
Formulation Stability

Solution stability: 24 hours at 2-8°C

Consistent injection preparation
Analytical Performance

Purity: ≥95% HPLC

Superior analytical precision
Stability Performance

Shelf life: 3 years at -20°C

Extended pharmaceutical integrity
Batch Reproducibility

Variation: ±3.0% between batches

Exceptional lot-to-lot consistency
Processing Performance

Reconstitution: Clear solution formation

Superior manufacturing efficiency

Safety Information

Pharmaceutical grade peptide requiring appropriate handling procedures. Use standard pharmaceutical safety protocols including proper ventilation, protective equipment, and trained personnel. Follow all applicable regulatory guidelines for pharmaceutical manufacturing and handling.

Pharmaceutical Material
Trained Personnel Required
cGMP Compliance

Storage & Handling

Store in original pharmaceutical packaging under frozen conditions. Maintain temperature and humidity conditions as specified. Use appropriate material handling equipment and ensure proper documentation for pharmaceutical traceability and regulatory compliance.

Frozen storage (-20°C)
Protect from light
Original pharmaceutical packaging
Complete documentation required

Chemical Mechanisms & Reaction Pathways

Liraglutide exhibits GLP-1 receptor agonism through incretin mimetic activity and glucose-dependent insulin release, enabling precise antidiabetic applications with predictable pharmacokinetic pathways and quantitative glycemic control.

GLP-1 Receptor Agonism

Selective activation of glucagon-like peptide-1 receptors

Therapeutic mechanism for glucose regulation
Incretin Activity

Glucose-dependent insulin secretion enhancement

Essential for glycemic control
Gastric Motility

Delayed gastric emptying and satiety enhancement

Enables selective therapeutic applications
Weight Management

Appetite suppression and weight loss promotion

Controlled therapeutic environment for diabetes treatment

Regulatory Compliance & Documentation

Comprehensive regulatory compliance ensures global pharmaceutical market access with complete documentation packages supporting international standards and therapeutic method validations.

USP Grade Specifications

United States Pharmacopeia pharmaceutical grade standards compliance

EP Monograph Standard

European Pharmacopoeia standard for pharmaceutical specifications

IP Grade Available

Indian Pharmacopoeia specifications for pharmaceutical analysis

ICH Guidelines

International Conference on Harmonisation pharmaceutical compliance

Method Validation

Supported pharmaceutical method validation documentation

SDS Documentation

Multi-language Safety Data Sheets (16 sections, GHS compliant)

Technical Support & Value-Added Services

DRAVYOM's pharmaceutical development team provides comprehensive formulation support, stability testing, and regulatory services to optimize Liraglutide performance in your specific pharmaceutical applications.

Formulation Development
  • Pharmaceutical formulation optimization support
  • Stability testing guidance
  • Bioavailability and bioequivalence studies
  • Custom pharmaceutical procedures
Analytical Services
  • Certificate of Analysis verification
  • Custom purity analysis
  • Impurity profiling and identification
  • Method validation support
Technical Support
  • Pharmaceutical troubleshooting consultation
  • Storage and handling guidance
  • Safety training and protocols
  • cGMP best practices
Supply Solutions
  • Consistent batch scheduling
  • Emergency supply arrangements
  • Custom packaging options
  • Global distribution network

Environmental Impact & Sustainability

Our Liraglutide production emphasizes environmental responsibility through sustainable manufacturing practices, waste minimization, and comprehensive environmental impact management for pharmaceutical operations.

Waste Minimization

Optimized production with minimal waste generation

Water Treatment

Advanced wastewater treatment and recycling systems

Clean Production

Energy-efficient synthesis with emission controls

Safe Disposal

Comprehensive guidance for pharmaceutical waste management

ISO 14001

Environmental management system certified production

Container Recycling

Pharmaceutical container return and recycling programs

Manufacturing Excellence & Quality Control

DRAVYOM's state-of-the-art pharmaceutical manufacturing facility employs advanced purification technology and continuous monitoring systems to ensure consistent Liraglutide quality and performance across all production batches.

Production Process

Advanced synthesis and purification in controlled cGMP environment

Multi-stage purification for pharmaceutical grade quality
Quality Testing

Comprehensive analytical testing protocol including purity, impurities, and stability

HPLC verification and spectroscopic analysis
Quality Systems

ISO 9001:2015 quality management with cGMP compliance

Continuous improvement and method validation
Packaging Control

Pharmaceutical grade containers with controlled atmosphere packaging

Light protection and contamination prevention

Market Applications & Performance Data

Comprehensive pharmaceutical data demonstrating Liraglutide effectiveness across diverse diabetes and weight management applications with quantified performance metrics and clinical validation.

Pharmaceutical Manufacturing
Purity: >95% pharmaceutical grade Bioavailability: >85% in formulations Stability: 2 years shelf life
Research Institutions
Publications: 800+ cited studies Clinical Trials: 100+ ongoing studies Innovation: Diabetes and obesity therapy development
Contract Manufacturing
Reliability: 99.5% batch consistency Compliance: 100% regulatory approval Efficiency: 30% cost reduction

DRAVYOM Competitive Advantages

Superior Purity

Consistently exceeds pharmacopeia specifications with ultra-low impurities and exceptional pharmaceutical performance

Reliable Supply

Guaranteed availability with strategic inventory management and pharmaceutical-grade production scheduling

Pharmaceutical Expertise

Dedicated pharmaceutical development team provides formulation and regulatory support

Quality Assurance

Traceable certificates with comprehensive analytical data and stability studies

Global Standards

International compliance with USP, EP, and ICH guidelines for worldwide acceptance

Partnership Approach

Collaborative relationships with pharmaceutical manufacturers and custom development services